Preclinical Results for Acetylon Pharmaceuticals' Selective HDAC1/2 Inhibitor for the Treatment of Sickle Cell Disease and Beta-Thalassemia Presented at American Society of Hematology 2012
12/11/2012 9:44:43 AM
BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia. The study results suggest that selective inhibition of the epigenetic regulators of gene expression, HDACs 1 and 2, could represent a refined and targeted approach for the treatment of SCD and bT through the induction of disease-corrective fetal hemoglobin (HbF) in human red blood cell progenitors.
comments powered by